Vaxart (VXRT) Announces Quarterly Earnings Results

Vaxart (NASDAQ:VXRT) announced its quarterly earnings data on Friday, November 9th. The biotechnology company reported ($0.92) earnings per share (EPS) for the quarter, MarketWatch Earnings reports. Vaxart had a negative return on equity of 198.56% and a negative net margin of 330.79%. The firm had revenue of $0.28 million during the quarter.

VXRT stock traded down $0.06 during trading on Monday, hitting $3.02. 33,800 shares of the company’s stock traded hands, compared to its average volume of 155,558. The company has a current ratio of 2.39, a quick ratio of 2.39 and a debt-to-equity ratio of 0.15. Vaxart has a 52 week low of $2.37 and a 52 week high of $9.46.

ILLEGAL ACTIVITY WARNING: “Vaxart (VXRT) Announces Quarterly Earnings Results” was first published by Baseball Daily News and is the sole property of of Baseball Daily News. If you are viewing this report on another site, it was stolen and reposted in violation of United States and international trademark and copyright law. The legal version of this report can be viewed at https://www.baseballdailydigest.com/news/2018/12/03/vaxart-vxrt-issues-earnings-results.html.

Vaxart Company Profile

Vaxart, Inc, a clinical-stage company, focuses on developing oral recombinant vaccines based on its proprietary oral vaccine delivery platform. The company's platform delivers various recombinant protein antigens, such as those used in influenza, hepatitis B, and human papilloma virus (HPV) vaccines, as well as other recombinant vaccines.

See Also: What is the Rule of 72?

Earnings History for Vaxart (NASDAQ:VXRT)

Receive News & Ratings for Vaxart Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vaxart and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply